24 results about "Taxifolin" patented technology

The invention belongs to the technical field of taxifolin, and discloses a taxifolin compound, a preparation method thereof and application of the taxifolin compound in the fields of relieving, oil control and senility .The taxifolin compound contains modified beta-cyclodextrin, taxifolin and auxiliary components, and the modified beta-cyclodextrin is modified through a polar group; the auxiliary component is selected from one or more of a hydrophilic polymer, an antioxidant and a targeting carrier. The taxifolin compound provided by the invention is high in inclusion rate and good in water solubility, the polar group modified beta-cyclodextrin can finely adjust the space structure of a cavity to expand an opening, the polar group modified beta-cyclodextrin has high matching degree with the molecular structure of taxifolin, a hydrophobic aromatic ring of taxifolin can enter the cavity to be combined with a hydrophobic core, and the taxifolin compound is high in inclusion rate and good in water solubility. The water solubility is good. The taxifolin compound provided by the invention is strong in anti-inflammatory ability, has a remarkable soothing effect, and also has excellent anti-aging and oil-control effects.

The invention provides application of pinostrobin in preparation of a medicine for treating gastric ulcer, and belongs to the technical field of biological medicine. The pinostrobin provided by the invention realizes the anti-gastric ulcer effect by improving the gastric mucosa blood flow volume, inhibiting inflammatory reaction, inhibiting oxidation reaction and maintaining the integrity of the gastric mucus barrier. Pinostrobin can reduce the gastric ulcer area of rats and increase the pain threshold value; the content of ET-1 in plasma is reduced, and the repairing effect of gastric mucosa is enhanced; the contents of TNF-alpha and IL-6 are reduced, the content of IL-10 is increased, and the anti-inflammatory effect is enhanced; the content of T-SOD in plasma is increased, the content of MPO is reduced, and the antioxidant effect is enhanced. The pinostrobin is expected to be used as a new medicine for treating gastric ulcer.

The invention provides an engineering bacterium and a method for synthesizing dacryitol. Wherein the engineering bacteria comprise II type terpenoid synthetase and I type terpenoid synthetase, and the sequence of the II type terpenoid synthetase contains any one of SEQ ID NOs: 41, 32, 42, 14, 15, 33, 3, 40, 39, 23, 4, 5, 10, 13, 19, 20, 24, 26, 27, 35, 36, 37 or 87, or contains a sequence having more than 70% of homology with the amino acid sequence; the sequence of the type I terpene synthase contains a sequence shown as SEQ ID NO: 101, SEQ ID NO: 118, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97 or SEQ ID NO: 88, or a sequence which has more than 70% of homology with the amino acid sequence. The method can solve the problem that high-efficiency biosynthesis of dacryitol is difficult in the prior art, and is suitable for the field of synthetic biology.

The invention discloses a construction method and application of a scutellaria baicalensis stem and leaf fingerprint spectrum, and belongs to the technical field of medicine quality control. The method comprises the following steps: preparing standard substance solutions of scutellarin, baicalin, taxifolin and isoschaftoside; preparing a scutellaria baicalensis stem and leaf sample solution; detection is carried out under specific conditions through high performance liquid chromatography, a standard fingerprint spectrum of the stems and leaves of scutellaria baicalensis is made by taking a standard chromatographic peak as a reference, and the relative standard deviation of the relative retention time does not exceed + / -20%. The method disclosed by the invention is high in precision, good in stability and excellent in repeatability, effective separation of four flavonoid components can be realized within 35 minutes, and the quality characteristics of stems and leaves of scutellaria baicalensis are comprehensively reflected. The invention further provides application of the fingerprint spectrum in quality analysis of the scutellaria baicalensis stem and leaf medicinal material and the extract thereof, and reliable technical support is provided for resource development and quality control of the scutellaria baicalensis stem and leaf.

The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and / or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and / or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.

The application belongs to the technical field of biological medicine, and particularly relates to application of SFRP1 in treatment of aortic aging drugs. SFRP1 can induce generation of vascular organoids, significantly antagonize vascular smooth muscle cell senescence induced by angiotensin II and bleomycin, enhance vascular smooth muscle cell activity, improve cell oxidative stress ability, reduce cell beta-galactosidase activity, reduce intracellular calcium deposition level, reduce phenotype conversion and reduce extracellular matrix remodeling. Taxifolin can significantly improve accelerated aortic aging in VSMC-specific Sfrp1 knockout mice. SFRP1 and / or Taxifolin both play an anti-aortic aging role, prevent and / or treat aortic aging related diseases. SFRP1 can be used as a screening target to screen drugs against cell senescence damage.

The invention relates to the technical field of pharmaceutical compositions, and discloses an anti-caries composition containing taxifolin as well as a preparation method and application of the anti-caries composition containing taxifolin, the anti-caries composition containing taxifolin comprises taxifolin and sodium fluoride, and the concentration ratio of taxifolin to sodium fluoride is 1mg / mL: 700ppm. Under the concentration, taxifolin and sodium fluoride generate a mutual promotion synergistic effect, and sodium fluoride obviously enhances the bacteriostatic action of taxifolin, obviously prolongs the growth delay phase of streptococcus mutans and reduces the viable count peak value in the logarithmic phase; the inhibition rate on biofilm formation is 57.4 + / -2.1%, and the antibacterial effect is remarkably enhanced; meanwhile, taxifolin enhances the demineralization resistance of sodium fluoride, and the demineralization resistance effect of only 700ppm of sodium fluoride is obviously superior to that of 1000ppm of sodium fluoride. The method disclosed by the invention has more excellent bacteriostatic activity, higher demineralization resistance and higher biological safety, and has great popularization and application values.

The application provides an engineering bacterium and a method for synthesizing taxifolin. The engineering bacterium comprises a type II terpenoid synthetase and a type I terpenoid synthetase. The type II terpenoid synthetase comprises any one of the sequences in SEQ ID NOs: 41, 32, 42, 14, 15, 33, 3, 40, 39, 23, 4, 5, 10, 13, 19, 20, 24, 26, 27, 35, 36, 37 or 87, or a sequence with more than 70% homology with the amino acid sequence. The type I terpenoid synthetase comprises the sequence in SEQ ID NO: 101, 118, 92, 93, 94, 95, 96, 97 or 88, or a sequence with more than 70% homology with the amino acid sequence. The application can solve the problem that it is difficult to efficiently biosynthesize taxifolin in the prior art, and is suitable for the field of synthetic biology.

The invention discloses a method for biosynthesizing luteolin or piceatannol by using CO2 and application of the method, and relates to the field of bioengineering. According to the invention, photosynthetic microorganisms such as blue-green algae are subjected to genetic modification, and a biosynthetic pathway of luteolin or piceatannol and a reducing power regeneration pathway represented by phosphite dehydrogenase are modularly assembled in the photosynthetic microorganisms; the obtained genetic engineering photosynthetic microorganism can directly and efficiently convert inexhaustible solar energy, greenhouse gas CO2 and phosphite into high-value luteolin or piceatannol, so that consumption of organic carbon sources of food crops and the like and complex steps and environmental pollution of traditional plant extraction or chemical synthesis are avoided. According to the method provided by the invention, the raw material cost is greatly reduced, the greenhouse gas CO2 can be absorbed, a promising technical approach is provided for replacing the traditional production mode depending on plant extraction, chemical synthesis or heterotrophic fermentation, and the method has important practical significance and industrial application value.

The invention relates to a fingerprint spectrum of traditional Chinese medicine granules for treating nasosinusitis as well as a construction method and a detection method thereof, and belongs to the technical field of traditional Chinese medicine analysis. Comprising the following steps: step 1, preparing a test solution; 2, preparing a mixed reference substance solution; and step 3, performing high performance liquid chromatography detection. The invention further discloses a fingerprint spectrum and a detection method of the traditional Chinese medicine granules for treating nasosinusitis. According to the method disclosed by the invention, the characteristic chromatogram of the traditional Chinese medicine granules for treating nasosinusitis, which is good in separation degree, large in information amount, more in peak identification information and stable in base line, can be obtained, seven common characteristic peaks are determined, and the characteristic peaks of ferulic acid, chlorogenic acid, taxifolin, baicalin, liquiritin, ammonium glycyrrhizinate and quercitrin are successfully identified; the oneness and one-sidedness of quality control are avoided, and the method can be used for quality control and evaluation of the traditional Chinese medicine granules for treating nasosinusitis.

A method for enzymatically producing taxifolin, and the enzyme for that purpose are provided. [Solution] A method for producing taxifolin, comprising converting quercetin to taxifolin using at least one enzyme selected from the group consisting of an enzyme having the amino acid sequence of SEQ ID NO: 1, an enzyme having the amino acid sequence of SEQ ID NO: 2, an enzyme having the amino acid sequence of SEQ ID NO: 3, and an enzyme having an amino acid sequence that is at least 90% identical to any of SEQ ID NOs: 1 to 3.

The purpose of the present invention is to provide a prophylactic, therapeutic or ameliorating drug or food for non-alcoholic steatohepatitis-derived hepatocarcinoma. The present invention pertains to a CD36 inhibitor comprising taxifolin or a salt thereof. The present invention also pertains to a prophylactic, therapeutic or ameliorating drug or food composition for non-alcoholic steatohepatitis-derived hepatocarcinoma.

The application discloses application of a taxifolin in treatment of Alzheimer's disease, SCA intervention can significantly improve cognitive memory dysfunction and protect brain tissue structure integrity; SCA can reduce abnormal deposition of A beta in the brain, reduce the number and distribution range of A beta positive plaque and alleviate AD core pathological damage; SCA can improve central nervous system pathological damage and cognitive dysfunction by regulating intestinal microecology. The application has important scientific significance and clinical transformation value for developing a safe and efficient new method for intervention of Alzheimer's disease.

[Problem] A simpler method is strongly required in order to improve the bioavailability of taxifolin. [Solution] The problem is solved by providing an oral composition comprising: (A) taxifolin or a taxifolin-containing extract; and (B) at least one selected from the group consisting of Piper longum, an extract thereof, hydrogen, and a hydrogen-occluding mineral powder.

The invention provides a hair care composition comprising: (i) taxifolin glucoside; (ii) N-acetyl tyrosine; (iii) at least one lipid PPAR[alpha] activator. The invention also provides uses and methods comprising the hair care composition of the invention.

The application belongs to the field of biological medicine, and particularly relates to the use of mulberroside A compounds in the preparation of drugs for treating chronic kidney disease. The mulberroside A compounds can inhibit the TGF-beta signal pathway, reduce the expression of fibrosis-related genes and proteins, reduce the fibrosis area, and alleviate the damage to the renal tubules, thereby treating renal fibrosis of chronic kidney disease, providing a new choice for clinically treating renal fibrosis of chronic kidney disease, and having a good application prospect.

The invention relates to the field of plant molecular biology, in particular to a pinus massoniana pinocembrin methyltransferase gene, a product and application. The invention relates to a pinus massoniana pinocembrin methyltransferase gene. The nucleotide sequence of the pinus massoniana pinocembrin methyltransferase gene is shown as SEQ ID NO. 1. The pinus massoniana pinocembrin methyltransferase gene is cloned from pinus massoniana pinocembrin for the first time, the nucleotide sequence and the amino acid sequence of the pinus massoniana pinocembrin methyltransferase gene are determined, the blank that in the prior art, pinus massoniana pinocembrin methyltransferase and biosynthetic genes of pinus massoniana pinocembrin methyltransferase are unknown is filled up, and theoretical and basic support is provided for related research of pinus massoniana A recombinant vector and engineering bacteria are obtained through genetic recombination of the pinus massoniana pinocembrin methyltransferase, the pinus massoniana pinocembrin methyltransferase is successfully purified to obtain the pinus massoniana pinocembrin methyltransferase, in an in-vitro enzyme activity experiment, the pinus massoniana pinocembrin methyltransferase can catalyze pinocembrin to synthesize pinocembrin monomethyl ether, and the pinus massoniana pinocembrin methyltransferase has

The invention generally provides a method for preparing a class of flavanone derivatives and application of the flavanone derivatives as a sweetness enhancer. In particular, the present invention provides a method of preparing a compound of Formula (I) as defined herein by reacting a precursor compound of Formula (Ia) as defined herein with an acyltransferase. In some embodiments, the compound of formula (Ia) is hesperidin, taxifolin, dihydrotamaristin, 3 '-O-methyl taxifolin, pinocembrin, 5-deoxyhesperidin, 5-deoxytaxifolin, 5-deoxydihydrotamaristin, 5-deoxy-3'-O-methyl taxifolin, or 5-deoxypinocembrin. In some embodiments, the compound shown in the formula (I) is hesperidin-3-O-acetate, taxifolin-3-O-acetate, dihydrotaxifolin-3-O-acetate, 3 '-O-methyl taxifolin-3-O-acetate, pinocembrin-3-O-acetate, 5-deoxyhesperidin-3-O-acetate and 5-deoxytaxifolin-3-O-acetate, and the structural formula of the compound shown in the formula (I) is shown in the description. The compound is prepared from 5-deoxytamarix flavin-3-O-acetate, 5-deoxydihydrotamarix flavin-3-O-acetate, 5-deoxy-3 '-O-methyl taxifolin-3-O-acetate or 5-deoxybrepinin-3-O-acetate. The invention also relates to acyltransferases useful in this method and certain compositions comprising such flavanone derivatives, such as compositions comprising such flavanone derivatives and one or more other sweeteners.

The application belongs to the field of medicine and chemical industry, and relates to a biflavonoid compound and an extraction method and application thereof. A structural formula of the biflavonoid compound is as shown in formula 1: The biflavonoid compound is prepared through a series of steps such as crushing, extraction, concentration, extraction, column chromatography, HPLC and drying, and has high purity. The anti-HCC activity of the C-O-C bonded biflavonoid compound is better than that of reported C-C bonded amentoflavone and C-O-C bonded taxifolin, and therefore the biflavonoid compound has high potential for preparing hepatocellular carcinoma drugs.

The present invention relates to the field of pharmaceutical technology, and more specifically, to the use of a formula of active ingredients of Gastrodia elata for treating cardiovascular and cerebrovascular diseases caused by diabetes. The formula comprises the following ingredients: n-butyl lactone, esculetin, lignoceric acid, monomelite glycoside, lonicerin A, hyoscyamine, berberine saponin II, palmatine, taxifolin, and angoside B. The drug prepared using this formula exhibits excellent therapeutic effects on cardiovascular and cerebrovascular diseases caused by diabetes.

The invention belongs to the technical field of biological medicine, and particularly relates to a pinocembrin and aminoglycoside medicine synergistic antibacterial composition and application thereof.The pinocembrin and aminoglycoside medicine are compounded, the sensitivity of the aminoglycoside medicine can be recovered, the toxic and side effects of antibacterial medicine can be remarkably reduced, and the antibacterial effect is good. The antibacterial activity on vibrio parahaemolyticus is improved, and a relatively good antibacterial effect is displayed. The pinocembrin and aminoglycoside drug compounded composition obtained by the invention has the advantages of low toxicity and high curative effect, and provides a new treatment strategy for clinical treatment of vibrio parahaemolyticus infectious diseases.

The purpose of the present invention is to provide a drug or food for preventing, treating or ameliorating hepatocellular carcinoma derived from non-alcoholic steatohepatitis. The present invention relates to a CD36 inhibitor comprising taxifolin or a salt thereof. In addition, the present invention also relates to a pharmaceutical or food composition for preventing, treating or ameliorating hepatocellular carcinoma derived from non-alcoholic steatohepatitis, said pharmaceutical or food composition containing the CD36 inhibitor.

The invention discloses a taxifolin-containing solid beverage and a preparation method thereof, and belongs to the technical field of probiotic beverages, the taxifolin is subjected to water-soluble modification through debranched short amylose to realize high water solubility and high bioavailability, and probiotics, small molecular protein peptide and prebiotics are combined for compounding to realize synergistic interaction of physiological activities of all components, so that the taxifolin-containing solid beverage has a good effect on preventing and treating the taxifolin, and the taxifolin-containing solid beverage is prepared. Meanwhile, the taxifolin-containing solid beverage has good solubility, is not easy to enrich after being brewed, forms precipitates at the bottom of a cup, and has the effects of nutrition supplement, intestinal tract conditioning and antioxidant protection; the liquid modified taxifolin is converted into the porous solid water-soluble taxifolin through spray drying, the water solubility is guaranteed, the porous structure enables the taxifolin to rapidly absorb water, permeate, instantly dissolve and release the internal taxifolin when meeting water, rapid dissolution during brewing is guaranteed, and the antioxidant and anti-inflammatory physiological activity of the taxifolin is reserved.

The present invention relates to the use of baicalein and its composition in the preparation of drugs for delaying ovarian senescence. The present invention provides the use of baicalein alone or in combination with taxifolin in the preparation of drugs for regulating follicular development, inhibiting ovulation and delaying ovarian senescence; the present invention has confirmed that the composition of baicalein alone or in combination with taxifolin can effectively inhibit ovarian angiogenesis, thereby inhibiting the development of growing follicles, and ultimately achieving the purpose of protecting female reproductive reserve, delaying ovarian senescence and protecting fertility.